Skip to main content
Caplight Logo









K2 Oncology

K2 Oncology

Private
BeijingHealthcare & Life Scienceshttps://k2oncology.cn/

Last Round

Series B

Aug 4, 2022

Total Funding Raised

$1.5M

Company Overview

K2 Oncology is a biotechnology company that specializes in organoid technology, providing anti-tumor drug R&D services and precision medicine solutions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Keywords

organoid technologypatient-derived organoidPDOdrug screeningprecision medicinecontract research organizationCROorganoid culture mediahigh-throughput screeningtumor organoid3D cell culturedrug discoverylab-grown tumorspersonalized oncologymatrix gel

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

K2 Oncology Comparables

Compare K2 Oncology with similar companies based on industry and business-model similarity.

K2 Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AimingMed
89%
D1 Medical Technology
88%
bioGenous Biotechnology
87%

K2 Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 4, 2022
Series AAug 1, 2018
AngelSep 1, 2016

K2 Oncology Investors

Notable investors and investment history

K2 Oncology investors
InvestorRounds
Delian CapitalSeries A
Tongsheng CapitalSeries A
Zhongguancun Development GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 4, 2022

    Completed a Series B funding round.

  • Aug 1, 2018

    Led by Delian Capital with participation from Tongsheng Capital and Zhongguancun Development Group.

K2 Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

K2 Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about K2 Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Year Founded2016
Last FundingAug 4, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?